Traws Pharma Inc. Common Stock (TRAW)
Stock · NASDAQ · Health Care
$0.3877as of 10/16/2026
Price chart
Active signals
TRAW Signal Track Record
How signals performed across all stocks →What TRAW's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 23 | -8.3% | 30% | October 9, 2026 |
| Volume Spike | 22 | +4.3% | 55% | September 24, 2026 |
| Bollinger Band Breakout | 19 | -10.1% | 37% | September 29, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -15.0% | 14% | May 15, 2026 |
| Any 20-session window (baseline) | -6.8% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TRAW
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in d…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- www.trawspharma.com/
Fundamentals
- 1-day range
- $0.3682$0.4137
- Market cap
- $8.21M
- P/E (trailing)
- —
- P/E (forward)
- -0.20
- EPS (trailing)
- $-2.11
- Dividend yield
- —
- Beta
- 1.59
- Avg. volume
- 584.8K
How Traws Pharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 31, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Traws Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TRAWTraws Pharma Inc. Common Stock$0.37▼ 7.50%Market cap $8.21MP/E —$0.391$3.23
- SNGXSoligenix Inc. Common Stock$0.35▼ 2.78%Market cap $8.24MP/E —$0.28$1.76
- KAPAKairos Pharma Ltd. Common Stock$0.601▼ 10.43%Market cap $8.35MP/E —$0.7108$9.17
- ENSCEnsysce Biosciences Inc. Common Stock$0.518▼ 13.38%Market cap $8.06MP/E —$0.23$2.75
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
- XCURExicure Inc. Common Stock$1.12▲ 0.00%Market cap $8.60MP/E —$0.936$9.48
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TRAW Traws Pharma Inc. Common Stock | $8.21M | — | $0.37 | ▼ 7.50% | $0.391$3.23 |
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.35 | ▼ 2.78% | $0.28$1.76 |
| KAPA Kairos Pharma Ltd. Common Stock | $8.35M | — | $0.601 | ▼ 10.43% | $0.7108$9.17 |
| ENSC Ensysce Biosciences Inc. Common Stock | $8.06M | — | $0.518 | ▼ 13.38% | $0.23$2.75 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.12 | ▲ 0.00% | $0.936$9.48 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/28/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 9/25/2026
- Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving PremarketBenzinga · 9/25/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/22/2026
Insider Activity
Insider Actions →- Pauza Charles David · July 9, 2026 · Grant97.0K
- Savchuk Nikolay · July 9, 2026 · Grant93.0K
- CAUTREELS WERNER · July 9, 2026 · Grant14.2K
- Parker Charles Nolan · July 9, 2026 · Grant90.0K
- Redfield Robert · July 9, 2026 · Grant84.0K
- Clarke Trafford · July 9, 2026 · Grant14.2K
- Shoemaker Mary Teresa · July 9, 2026 · Grant14.2K
- Dukes Iain D. · July 9, 2026 · Grant274.0K
- Leaman John Harold · July 9, 2026 · Grant14.2K
- STOVER JACK E · July 9, 2026 · Grant14.2K
- ORBIMED ADVISORS LLC · April 16, 2026 · Buy1.79M
- ORBIMED ADVISORS LLC · April 16, 2026 · Buy597.7K @ $1.67
Institutional Ownership
March 31, 2026
- Total shares held
- 3.59M
- Total value held
- $6.57M
- Institutional holders
- 25
- Unknown730.0K
- Unknown678.1K
- Unknown605.5K
- Unknown511.7K
- Unknown417.0K
- Unknown194.5K
- Unknown154.1K
- Unknown77.1K
- Unknown61.2K
- Unknown55.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Traws Pharma listed in Benzinga health care movers
Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.
Traws Pharma listed in Benzinga health care movers. Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.